Comparing Meridian Bioscience (VIVO) & The Competition
Meridian Bioscience (NASDAQ: VIVO) is one of 84 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its peers? We will compare Meridian Bioscience to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, valuation and dividends.
This table compares Meridian Bioscience and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Meridian Bioscience Competitors||-127.18%||-36.38%||-10.25%|
This is a summary of recent recommendations for Meridian Bioscience and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Meridian Bioscience Competitors||174||1133||2481||89||2.64|
Meridian Bioscience currently has a consensus price target of $14.00, suggesting a potential downside of 11.39%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 8.66%. Given Meridian Bioscience’s peers stronger consensus rating and higher probable upside, analysts clearly believe Meridian Bioscience has less favorable growth aspects than its peers.
Meridian Bioscience pays an annual dividend of $0.50 per share and has a dividend yield of 3.2%. Meridian Bioscience pays out 98.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.8% and pay out 37.4% of their earnings in the form of a dividend.
Risk & Volatility
Meridian Bioscience has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Meridian Bioscience’s peers have a beta of 1.06, meaning that their average stock price is 6% more volatile than the S&P 500.
Earnings and Valuation
This table compares Meridian Bioscience and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Meridian Bioscience||$198.07 million||$52.80 million||30.98|
|Meridian Bioscience Competitors||$827.23 million||$159.49 million||36.89|
Meridian Bioscience’s peers have higher revenue and earnings than Meridian Bioscience. Meridian Bioscience is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
87.3% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 2.3% of Meridian Bioscience shares are owned by company insiders. Comparatively, 11.2% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Meridian Bioscience peers beat Meridian Bioscience on 10 of the 15 factors compared.
About Meridian Bioscience
Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers. Its segments include Diagnostics and Life Science. The Diagnostics segment includes manufacturing operations in Cincinnati, and the sale and distribution of diagnostic test kits in the countries consisting of North, Central and South America; Europe, the Middle East and Africa (EMEA), and other countries outside of the Americas and EMEA. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany, and Sydney, Australia.
Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.